Stevanato Group S.p.A. and Bexson Biomedical, Inc. Expand Collaboration to Treat a Range of Mental Health Conditions With an On-body Device
April 29 2022 - 9:00AM
Business Wire
Italian-based Stevanato Group S.p.A., a global provider of drug
containment, drug delivery and diagnostic solutions to the
pharmaceutical, biotechnology and life sciences industries, and
Bexson Biomedical, Inc., a research stage company developing
subcutaneous therapies for pain management and mental health
disorders, announced today that they have signed an agreement
expanding their collaboration.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220429005105/en/
The SG EZ-be Pod® is a discreet on-body
wearable device which will be ideally suited to the needs of
patients receiving treatments for pain management and mental health
disorders. (Photo: Business Wire)
This agreement between the companies will grant Bexson access to
the use of Stevanato’s wearable delivery system — a customized
version of the SG EZ-be Pod® — to develop new therapeutics to treat
a wide range of mental health conditions, including
treatment-resistant depression and PTSD.
Since 2020, Stevanato Group and Bexson have worked to optimize
the modularity of the SG EZ-be Pod®, for the treatment of chronic
and acute pain disorders. Such SG EZ-be Pod® is a small, wearable
infusion device that can be programmed for a wide range of
medications and delivery profiles, including at-home delivery. This
subcutaneous drug delivery system is the flagship for Bexson’s
proprietary ketamine formulation, BB106, and leverages Stevanato
Group’s existing technology and broad experience in medical device
innovation.
Bexson’s formulation technology has been shown to work with
several other classes of small molecules, beyond ketamine. This new
agreement allows the companies to evaluate further collaborations
with their device and drug platforms, respectively.
Combining these technologies aims to provide many of the dosing
control advantages of intravenous medication delivery without the
procedural burden and high cost. Oral delivery of psychedelic
compounds can lead to gastrointestinal tract discomfort, long and
expensive therapy sessions, and high response variability.
Subcutaneous delivery can also address many of the problems related
to poor bioavailability. This approach is also intended to permit
real-time dose attunement in an office setting, such as psychedelic
psychotherapy.
“We are grateful that our partners have the expertise and ideal
technology to deliver not just Bexson’s ketamine formulation, but
also other compounds optimized by Bexson’s formulation technology,”
said Jeffrey Becker, MD, Bexson’s Chief Scientific Officer. “We’re
actually just scratching the surface of what is possible. Beyond
pain management and mental health indications, this partnership
enables a dynamic small molecule delivery system that can be
applied to a surprisingly large number of important therapies.”
“We extend our collaboration with Bexson to better suit the
needs of patients from different therapeutic areas by developing
the modularity of our award-winning SG EZ-be Pod®. The extension of
our wearable device to a wider range of therapeutic areas may help
provide effective and comfortable treatments to patients suffering
from mental illness or chronic pain that impacts the quality of
their lives. The patient-centric SG EZ-be POD® is intended to give
patients more flexibility in the administration of medication
outside of clinics and hospitals. The partnership with Bexson
responds also to the need for sustainability on part of
pharmaceutical and biotechnology companies with the goal to reduce
the overall cost per treatment,” said Chief Business Officer Mauro
Stocchi, Stevanato Group.
About Bexson Biomedical, Inc.
Bexson Biomedical, Inc. is a research stage company developing
BB106, a ketamine therapy for pain management and mental health
disorders. According to recent market research pain following
surgery is a $35.5 billion market and is a leading cause of opioid
abuse and addiction. The Company is also applying their proprietary
delivery platform to several psychedelic and non-psychedelic
compounds. Visit at: www.bexsonbiomedical.com.
About Stevanato Group
Founded in 1949, Stevanato Group is a leading global provider of
drug containment, drug delivery and diagnostic solutions to the
pharmaceutical, biotechnology and life sciences industries. The
Group delivers an integrated, end-to-end portfolio of products,
processes and services that address customer needs across the
entire drug life cycle at each of the development, clinical and
commercial stages. Stevanato Group’s core capabilities in
scientific research and development, its commitment to technical
innovation and its engineering excellence are central to its
ability to offer value added solutions to clients. To learn more,
visit stevanatogroup.com.
Forward-Looking Statements
This press release may include forward-looking statements. The
words "aim", "opportunities" and similar expressions (or their
negative) identify certain of these forward-looking statements.
These forward-looking statements are statements regarding the
Company's intentions, beliefs, or current expectations concerning,
among other things, the Company's product offering, the potential
use of the Company's products to treat different diseases, growth
opportunities, market position, and the expansion of the Company's
integrated capabilities. The forward-looking statements in this
press release are based on numerous assumptions regarding the
Company's present and future business strategies and the
environment in which the Company will operate in the future.
Forward-looking statements involve inherent known and unknown
risks, uncertainties and contingencies because they relate to
events and depend on circumstances that may or may not occur in the
future and may cause the actual results, performance, or
achievements of the Company to be materially different from those
expressed or implied by such forward-looking statements. Many of
these risks and uncertainties relate to factors that are beyond the
Company's ability to control or estimate precisely, such as future
market conditions, currency fluctuations, the behavior of other
market participants, the actions of regulators, and other factors
such as the Company's ability to continue to obtain financing to
meet its liquidity needs, changes in the political, social and
regulatory framework in which the Company operates or in economic
or technological trends or conditions. Readers should therefore not
place undue reliance on these statements, particularly not in
connection with any contract or investment decision. Except as
required by law, the company assumes no obligation to update any
such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220429005105/en/
Media Bexson Biomedical teresa@spiral5.com
Stevanato Group media@stevanatogroup.com
Investor Relations Lisa Miles lisa.miles@stevanatogroup.com
Stevanato (NYSE:STVN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Stevanato (NYSE:STVN)
Historical Stock Chart
From Apr 2023 to Apr 2024